Targeted therapies, though effective in suppressing specific oncogenic pathways, frequently induce compensatory signaling cascades such as the c-Mesenchymal-Epithelial Transition factor (MET) or AXL Receptor Tyrosine Kinase (AXL) upregulation, enabling tumor escape mechanisms [94,95,96]. Here, AXL is linked to neoplasm.